These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 2164630)

  • 1. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.
    Wassermann K; Markovits J; Jaxel C; Capranico G; Kohn KW; Pommier Y
    Mol Pharmacol; 1990 Jul; 38(1):38-45. PubMed ID: 2164630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of DNA intercalator 3-nitrobenzothiazolo (3,2-a)quinolinium with DNA topoisomerases: a possible-mechanism for its biological activity.
    Báez A; Riou JF; Le Pecq JB; Riou G
    Mol Pharmacol; 1990 Mar; 37(3):377-82. PubMed ID: 2156151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
    Utsugi T; Mattern MR; Mirabelli CK; Hanna N
    Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
    Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
    Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives.
    Riou JF; Helissey P; Grondard L; Giorgi-Renault S
    Mol Pharmacol; 1991 Nov; 40(5):699-706. PubMed ID: 1658605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
    Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
    Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
    Zunino F; Capranico G
    Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
    Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
    Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin.
    Montaner B; Castillo-Avila W; Martinell M; Ollinger R; Aymami J; Giralt E; Pérez-Tomás R
    Toxicol Sci; 2005 Jun; 85(2):870-9. PubMed ID: 15788728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I.
    Covey JM; Jaxel C; Kohn KW; Pommier Y
    Cancer Res; 1989 Sep; 49(18):5016-22. PubMed ID: 2548707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antitumor agents targeting mammalian topoisomerases].
    Nakano H
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1550-5. PubMed ID: 1651681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.
    Ling YH; Priebe W; Perez-Soler R
    Cancer Res; 1993 Apr; 53(8):1845-52. PubMed ID: 8467504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
    Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
    Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of topoisomerase I function by coralyne and 5,6-dihydrocoralyne.
    Wang LK; Rogers BD; Hecht SM
    Chem Res Toxicol; 1996; 9(1):75-83. PubMed ID: 8924619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.